Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation

Akatsuki Saito(University of Miyazaki), Takashi Irie(Hiroshima University), Rigel Suzuki(Hokkaido University), Tadashi Maemura(University of Wisconsin–Madison), Hesham Nasser(Suez Canal University), Keiya Uriu(National Institute of Infectious Diseases), Yusuke Kosugi(National Institute of Infectious Diseases), Kotaro Shirakawa(Kyoto University), Kenji Sadamasu(Tokyo Metropolitan Institute of Public Health), Izumi Kimura(National Institute of Infectious Diseases), Jumpei Ito(National Institute of Infectious Diseases), Jiaqi Wu(Tokai University), Kiyoko Iwatsuki‐Horimoto(Tokyo University of Science), Mutsumi Ito(Tokyo University of Science), Seiya Yamayoshi(Tokyo University of Science), Samantha Loeber(University of Wisconsin–Madison), Masumi Tsuda(Hokkaido University), Lei Wang(Hokkaido University), Seiya Ozono(National Institute of Infectious Diseases), Erika P. Butlertanaka(University of Miyazaki), Yuri Tanaka(University of Miyazaki), Ryo Shimizu(Kumamoto University), Kenta Shimizu(Hokkaido University), Kumiko Yoshimatsu(Hokkaido University), Ryoko Kawabata(Hiroshima University), Takemasa Sakaguchi(Hiroshima University), Kenzo Tokunaga(National Institute of Infectious Diseases), Isao Yoshida(Tokyo Metropolitan Institute of Public Health), Hiroyuki Asakura(Tokyo Metropolitan Institute of Public Health), Mami Nagashima(Tokyo Metropolitan Institute of Public Health), Yasuhiro Kazuma(Kyoto University), Ryosuke Nomura(Kyoto University), Yoshihito Horisawa(Kyoto University), Kazuhisa Yoshimura(Tokyo Metropolitan Institute of Public Health), Akifumi Takaori‐Kondo(Kyoto University), Masaki Imai(Tokyo University of Science), Mika Chiba(National Institute of Infectious Diseases), Hirotake Furihata(National Institute of Infectious Diseases), Haruyo Hasebe(Kumamoto University), Kazuko Kitazato(Kumamoto University), Haruko Kubo(Hokkaido University), Naoko Misawa(National Institute of Infectious Diseases), Nanami Morizako(University of Miyazaki), Kohei Noda(Kumamoto University), Akiko Oide(National Institute of Infectious Diseases), Mai Suganami(National Institute of Infectious Diseases), Miyoko Takahashi(Tokai University), Kana Tsushima(Hokkaido University), Miyabishara Yokoyama(National Institute of Infectious Diseases), Yue Yuan(Kumamoto University), Shinya Tanaka(Hokusho University), So Nakagawa(Tokai University), Terumasa Ikeda(Kumamoto University), Takasuke Fukuhara(Health Sciences University of Hokkaido), Yoshihiro Kawaoka(University of Wisconsin–Madison), Kei Sato(National Institute of Infectious Diseases)
Nature
November 25, 2021
Cited by 676Open Access
Full Text

Abstract

Abstract During the current coronavirus disease 2019 (COVID-19) pandemic, a variety of mutations have accumulated in the viral genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, at the time of writing, four variants of concern are considered to be potentially hazardous to human society 1 . The recently emerged B.1.617.2/Delta variant of concern is closely associated with the COVID-19 surge that occurred in India in the spring of 2021 (ref. 2 ). However, the virological properties of B.1.617.2/Delta remain unclear. Here we show that the B.1.617.2/Delta variant is highly fusogenic and notably more pathogenic than prototypic SARS-CoV-2 in infected hamsters. The P681R mutation in the spike protein, which is highly conserved in this lineage, facilitates cleavage of the spike protein and enhances viral fusogenicity. Moreover, we demonstrate that the P681R-bearing virus exhibits higher pathogenicity compared with its parental virus. Our data suggest that the P681R mutation is a hallmark of the virological phenotype of the B.1.617.2/Delta variant and is associated with enhanced pathogenicity.


Related Papers